{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T02:38:17Z","timestamp":1780367897905,"version":"3.54.1"},"reference-count":89,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista de Psiquiatr\u00eda  y Salud Mental"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.rpsm.2018.03.006","type":"journal-article","created":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T18:08:18Z","timestamp":1529950098000},"page":"92-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Antipsic\u00f3ticos inyectables de liberaci\u00f3n prolongada para el tratamiento de la esquizofrenia en Espa\u00f1a"],"prefix":"10.1016","volume":"12","author":[{"given":"Celso","family":"Arango","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Baeza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Ca\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"de Dios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"D\u00edaz-Mars\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Paz","family":"Garc\u00eda-Portilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Guti\u00e9rrez-Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Olivares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Rico-Villademoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Rodr\u00edguez-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Mar\u00eda","family":"S\u00e1nchez-Morla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Segarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicto","family":"Crespo-Facorro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13 Suppl 1","key":"10.1016\/j.rpsm.2018.03.006_bib0450","first-page":"7S","article-title":"Clinical practice guidelines. Treatment of schizophrenia","volume":"50","year":"2005","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0455","doi-asserted-by":"crossref","first-page":"e1001861","DOI":"10.1371\/journal.pmed.1001861","article-title":"Antipsychotic maintenance treatment: Time to rethink?","volume":"12","author":"Moncrieff","year":"2015","journal-title":"PLoS Med"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0460","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1192\/bjp.bp.116.182683","article-title":"Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?","volume":"209","author":"Murray","year":"2016","journal-title":"Br J Psychiatry"},{"issue":"Suppl 5","key":"10.1016\/j.rpsm.2018.03.006_bib0465","first-page":"3","article-title":"Epidemiology, clinical consequences-., and psychosocial treatment of nonadherence in schizophrenia","volume":"67","author":"Leucht","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0470","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4088\/JCP.v63n1007","article-title":"Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature","volume":"63","author":"Lacro","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0475","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.rpsm.2016.04.001","article-title":"Adherence predicts symptomatic and psychosocial remission in schizophrenia: Naturalistic study of patient integration in the community","volume":"10","author":"Bernardo","year":"2017","journal-title":"Rev Psiquiatr Salud Ment"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0480","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2010.11.020","article-title":"Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials","volume":"127","author":"Leucht","year":"2011","journal-title":"Schizophr Res"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0485","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1176\/appi.ajp.2011.10081224","article-title":"A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia","volume":"168","author":"Tiihonen","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0490","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.schres.2011.10.022","article-title":"Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS)","volume":"134","author":"Grimaldi-Bensouda","year":"2012","journal-title":"Schizophr Res"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0495","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1176\/appi.ps.201500466","article-title":"Comparison of injectable and oral antipsychotics in relapse rates in a pragmatic 30-month schizophrenia relapse prevention study","volume":"67","author":"Buckley","year":"2016","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0500","doi-asserted-by":"crossref","first-page":"957","DOI":"10.4088\/JCP.13r08440","article-title":"Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies","volume":"74","author":"Kishimoto","year":"2013","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0505","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/schbul\/sbs150","article-title":"Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials","volume":"40","author":"Kishimoto","year":"2014","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0510","doi-asserted-by":"crossref","first-page":"568","DOI":"10.4088\/JCP.12r08167","article-title":"Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs","volume":"74","author":"Kirson","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"suppl 3","key":"10.1016\/j.rpsm.2018.03.006_bib0515","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4088\/JCP.15032su1","article-title":"The use of long-acting injectable antipsychotics in schizophrenia: Evaluating the evidence","volume":"77","author":"Correll","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0520","first-page":"175","article-title":"Shared decision making in mental health: Myths, barriers, and benefits","volume":"9","author":"Ramos Pozon","year":"2016","journal-title":"Rev Psiquiatr Salud Ment"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0525","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.encep.2014.12.002","article-title":"[A history of antipsychotic long-acting injections in the treatment of schizophrenia]","volume":"41","author":"Crocq","year":"2015","journal-title":"Encephale"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0530","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.4088\/JCP.14com09541","article-title":"Long-acting injectable antipsychotics: an underutilized treatment option","volume":"75","author":"Heres","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0535","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jamapsychiatry.2015.0485","article-title":"Expanding therapy with long-acting antipsychotic medication in patients with schizophrenia","volume":"72","author":"Carpenter","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0540","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.schres.2012.03.018","article-title":"Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009","volume":"138","author":"Gallego","year":"2012","journal-title":"Schizophr Res"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0545","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2147\/CEOR.S85514","article-title":"Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan","volume":"7","author":"Mahlich","year":"2015","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0550","first-page":"19","article-title":"Noninterventional, naturalistic, retrospective study to describe prescription patterns of long-acting injectable antipsychotics and the impact of introducing a new atypical antipsychotic in the spanish province of Tarragona catchment area","author":"Gaviria","year":"2017","journal-title":"Prim Care Companion CNS Disord"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0555","unstructured":"King S. Physician Views: Will approval of Aristada broaden the long-acting injectable antipsychotic market? 2015 [consultado 28 Mar 2017]. Disponible en: https:\/\/www.firstwordpharma.com\/node\/1321169"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0560","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1192\/bjp.bp.112.122978","article-title":"Attitudes towards psychiatric treatment and people with mental illness: changes over two decades","volume":"203","author":"Angermeyer","year":"2013","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0565","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1600-0447.2012.01826.x","article-title":"Evolution of public attitudes about mental illness: a systematic review and meta-analysis","volume":"125","author":"Schomerus","year":"2012","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0570","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1192\/bjp.195.52.s43","article-title":"Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review","volume":"52","author":"Waddell","year":"2009","journal-title":"Br J Psychiatry Suppl"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0575","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/1471-244X-13-261","article-title":"Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia","volume":"13","author":"Potkin","year":"2013","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0580","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/2045125314542098","article-title":"A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections. Ther","volume":"4","author":"Das","year":"2014","journal-title":"Adv Psychopharmacol"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0585","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.psychres.2008.11.003","article-title":"Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists","volume":"175","author":"Jaeger","year":"2010","journal-title":"Psychiatry Res"},{"issue":"5 Suppl 1","key":"10.1016\/j.rpsm.2018.03.006_bib0590","article-title":"A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part II-physician perspectives","volume":"58","author":"Iyer","year":"2013","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0595","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1192\/apt.11.3.203","article-title":"Why aren\u2019t depot antipsychotics prescribed more often and what can be done about it?","volume":"11","author":"Patel","year":"2005","journal-title":"Adv Psych Treat"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0600","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/YIC.0b013e3280c28424","article-title":"The attitude of patients towards antipsychotic depot treatment","volume":"22","author":"Heres","year":"2007","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0605","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1177\/0269881108092124","article-title":"Depot and oral antipsychotics: patient preferences and attitudes are not the same thing","volume":"23","author":"Patel","year":"2009","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0610","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/YIC.0b013e32835d30ae","article-title":"Comparison of attitudes toward long-acting injectable antipsychotics among psychiatrists and patients","volume":"28","author":"Kim","year":"2013","journal-title":"Int Clin Psychopharmacol"},{"issue":"Suppl 5","key":"10.1016\/j.rpsm.2018.03.006_bib0615","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00004850-199501005-00004","article-title":"Depot neuroleptics in relapse prevention: advantages and disadvantages","volume":"9","author":"Gerlach","year":"1995","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0620","doi-asserted-by":"crossref","first-page":"211","DOI":"10.4088\/JCP.v65n0211","article-title":"A pilot study of barriers to medication adherence in schizophrenia","volume":"65","author":"Hudson","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0625","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.4088\/JCP.13024tx1c","article-title":"Organizational barriers to using long-acting injectable antipsychotics in practice","volume":"75","author":"Kane","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0630","unstructured":"Bolet\u00edn Oficial del Estado. Ley 14\/1986, de 25 de abril, General de Sanidad. BOE n\u00fam. 102 de 29 de Abril de 1986."},{"key":"10.1016\/j.rpsm.2018.03.006_bib0635","series-title":"La psiquiatr\u00eda en la Espa\u00f1a de fin de siglo: un estudio sobre la reforma psiqui\u00e1trica y las nuevas reformas de atenci\u00f3n en salud mental","author":"Garc\u00eda Gonz\u00e1lez","year":"1998"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0640","series-title":"(Coordinador Cient\u00edfico). Estrategia en Salud Mental del Sistema Nacional de Salud, 2006","author":"G\u00f3mez Beneyto","year":"2007"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0645","unstructured":"World Health Organization ROfE. Mental Health. Data and statistics. Copenhagen: WHO Regional Office for Europe, 2016."},{"key":"10.1016\/j.rpsm.2018.03.006_bib0650","unstructured":"EUROSTAT. Mental health and related issues statistics [consultado 29 Mar 2017]. Disponible en: http:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php\/Mental_health_and_related_issues_statistics"},{"issue":"1 Suppl","key":"10.1016\/j.rpsm.2018.03.006_bib0655","first-page":"1","article-title":"Treatment adherence in schizophrenia. Spanish clinical consensus","volume":"35","author":"Roca","year":"2007","journal-title":"Actas Esp Psiquiatr"},{"issue":"Suppl 2","key":"10.1016\/j.rpsm.2018.03.006_bib0660","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4088\/JCP.13065su1c.07","article-title":"Patient outcomes within schizophrenia treatment: a look at the role of long-acting injectable antipsychotics","volume":"75","author":"Bera","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0665","unstructured":"Grupo de trabajo del CIBERSAM para la elaboraci\u00f3n de una gu\u00eda cl\u00ednica y terap\u00e9utica para primeros episodios psic\u00f3ticos en la infancia y adolescencia. Gu\u00eda cl\u00ednica y terap\u00e9utica para primeros episodios psic\u00f3ticos en la infancia y adolescencia Informe de consenso de Recomendaciones: Centro de Investigaci\u00f3n Biom\u00e9dica en Red - CIBER, 2015 [consultado 29 Mar 2017]. Disponible en: http:\/\/www.ciberisciii.es\/ficheros\/SAM\/Gu%C3%ADaPEPinfanciaAdolescencia_v5.0.pdf"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0670","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/1471-244X-13-340","article-title":"Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness","volume":"13","author":"Llorca","year":"2013","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0675","unstructured":"National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. NICE guidelines [cg178]: National Institute for Health and Care Excellence, 2014."},{"key":"10.1016\/j.rpsm.2018.03.006_bib0680","unstructured":"Work Group on Schizophrenia. Practice Guideline for the Treatment of Patients With Schizophrenia, Second Edition. Washington: American Psychiatric Association; 2010."},{"key":"10.1016\/j.rpsm.2018.03.006_bib0685","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archpsyc.64.1.19","article-title":"Lifetime prevalence of psychotic and bipolar I disorders in a general population","volume":"64","author":"Perala","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0690","first-page":"i375","article-title":"\u00abSchizophrenia\u00bb does not exist","volume":"352","author":"Van Os","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0695","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.rpsm.2017.01.001","article-title":"When the healthcare does not follow the evidence: The case of the lack of early intervention programs for psychosis in Spain","volume":"10","author":"Arango","year":"2017","journal-title":"Rev Psiquiatr Salud Ment"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0700","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jpsychires.2012.05.001","article-title":"Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study","volume":"46","author":"Caseiro","year":"2012","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0705","first-page":"32","article-title":"Managing first-episode psychosis: an early stage of schizophrenia with distinct treatment needs","volume":"14","author":"Gardner","year":"2015","journal-title":"Current Psychiatry"},{"issue":"Suppl 2","key":"10.1016\/j.rpsm.2018.03.006_bib0710","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S0924-9338(14)70001-X","article-title":"Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics","volume":"29","author":"Heres","year":"2014","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0715","doi-asserted-by":"crossref","first-page":"492","DOI":"10.4088\/JCP.14m09540","article-title":"Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study","volume":"77","author":"Mayoral-van Son","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0720","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamapsychiatry.2013.19","article-title":"Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction\/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial","volume":"70","author":"Wunderink","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"4.","key":"10.1016\/j.rpsm.2018.03.006_bib0725","article-title":"A Pharmacovigilance Study in first episode of psychosis: Psychopharmacological interventions and safety profiles in the PEPs project","volume":"19","author":"Bioque","year":"2016","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0730","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/jamapsychiatry.2015.0500","article-title":"Treatment of young people with antipsychotic medications in the United States","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0735","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/070674371305800608","article-title":"A population-based study of antipsychotic prescription trends in children and adolescents in British Columbia, from 1996 to 2011","volume":"58","author":"Ronsley","year":"2013","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0740","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jaac.2013.02.008","article-title":"Practice parameter for the assessment and treatment of children and adolescents with schizophrenia","volume":"52","author":"McClellan","year":"2013","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0745","first-page":"S280","article-title":"Attitudes of children and adolescents and their caregivers towards long-acting injectable antipsychotics in a cohort of youth initiating oral antipsychotic treatment","volume":"38","author":"Correll","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0750","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1089\/cap.2016.0055","article-title":"Long-acting injectable antipsychotics in children and adolescents","volume":"27","author":"Lytle","year":"2017","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0755","author":"Fortea","year":"2016","journal-title":"Long-acting injectable atypical antipsychotic in adolescent population: an observational study. 29th European College Neuropsychopharmacology Congress. Viena, Austria"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0760","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1089\/cap.2011.0035","article-title":"Paliperidone palmitate in a child with autistic disorder. J Child","volume":"21","author":"Kowalski","year":"2011","journal-title":"Adolesc Psychopharmacol"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0765","doi-asserted-by":"crossref","first-page":"65","DOI":"10.9758\/cpn.2014.12.1.65","article-title":"Successful treatment of anorexia nervosa in a 10-year-old boy with risperidone long-acting injection","volume":"12","author":"Umehara","year":"2014","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0770","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1136\/bmj.1.6064.835-c","article-title":"Use of depot tranquilisers in disturbed adolescent girls","volume":"1","author":"Perinpanayagam","year":"1977","journal-title":"Br Med J"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0775","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/wps.20060","article-title":"Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies","volume":"12","author":"Kane","year":"2013","journal-title":"World Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0780","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1001\/jamapsychiatry.2015.0270","article-title":"Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial","volume":"72","author":"Subotnik","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0785","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.schres.2015.08.015","article-title":"Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia","volume":"169","author":"Schreiner","year":"2015","journal-title":"Schizophr Res"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0790","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.4088\/JCP.14m09168","article-title":"Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study","volume":"75","author":"Kane","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0795","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.4088\/JCP.14m09741","article-title":"A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia","volume":"76","author":"Meltzer","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0800","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.schres.2016.09.014","article-title":"Antipsychotic long-acting injections: A community-based study from 2007 to 2014 of prescribing trends and characteristics associated with initiation","volume":"178","author":"Verdoux","year":"2016","journal-title":"Schizophr Res"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0805","unstructured":"Lauriello J, Campbell AR. Pharmacotherapy for schizophrenia: Long-acting injectable antipsychotic drugs. 2016 [consultado 17 Dic 2016]. Disponible en: http:\/\/www.uptodate.com\/contents\/pharmacotherapy-for-schizophrenia-long-acting-injectable-antipsychotic-drugs"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0810","unstructured":"UMC Utrecht. European Long-acting Antipsychotics in Schizophrenia Trial (EULAST). ClinicalTrials.gov Identifier: NCT02146547, 2016."},{"key":"10.1016\/j.rpsm.2018.03.006_bib0815","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.schres.2016.07.018","article-title":"Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics","volume":"176","author":"Misawa","year":"2016","journal-title":"Schizophr Res"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0820","doi-asserted-by":"crossref","first-page":"669","DOI":"10.4088\/JCP.11m07074","article-title":"Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial","volume":"73","author":"Covell","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0825","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1001\/jama.2014.4310","article-title":"Effectiveness of paliperidone palmitate vs.haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial","volume":"311","author":"McEvoy","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0830","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.pnpbp.2010.11.008","article-title":"A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia","volume":"35","author":"Pandina","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0835","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.pnpbp.2011.02.001","article-title":"A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia","volume":"35","author":"Li","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0840","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.schres.2015.07.007","article-title":"Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia","volume":"168","author":"Naber","year":"2015","journal-title":"Schizophr Res"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0845","first-page":"99","article-title":"Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics","volume":"12","author":"de Bartolomeis","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0850","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/NMD.0b013e31829829c4","article-title":"Clinicians\u2019 attitudes toward the use of long-acting injectable antipsychotics","volume":"201","author":"Samalin","year":"2013","journal-title":"J Nerv Ment Dis"},{"issue":"Suppl 1","key":"10.1016\/j.rpsm.2018.03.006_bib0855","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.encep.2012.03.005","article-title":"[Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists]","volume":"39","author":"Misdrahi","year":"2013","journal-title":"Encephale"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0860","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/104012371402600104","article-title":"Barriers to utilizing long-acting injectable antipsychotic medications","volume":"26","author":"Getzen","year":"2014","journal-title":"Ann Clin Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0865","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2147\/PPA.S53795","article-title":"Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia","volume":"7","author":"Kaplan","year":"2013","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0870","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1471-244X-12-122","article-title":"Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations","volume":"12","author":"Rossi","year":"2012","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0875","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.4088\/JCP.v67n1216","article-title":"Attitudes of psychiatrists toward antipsychotic depot medication","volume":"67","author":"Heres","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0880","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3111\/13696998.2014.1001514","article-title":"Healthcare utilization and costs of Veterans Health Administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics","volume":"18","author":"Baser","year":"2015","journal-title":"J Med Econ"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0885","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.eurpsy.2009.12.020","article-title":"Psychiatrists\u2019 attitude to antipsychotic depot treatment in patients with first-episode schizophrenia","volume":"26","author":"Heres","year":"2011","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.006_bib0890","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1017\/S0033291702006797","article-title":"Psychiatrists\u2019 attitudes to maintenance medication for patients with schizophrenia","volume":"33","author":"Patel","year":"2003","journal-title":"Psychol Med"}],"container-title":["Revista de Psiquiatr\u00eda  y Salud Mental"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1888989118300405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1888989118300405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:32:16Z","timestamp":1761823936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1888989118300405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":89,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S1888989118300405"],"URL":"https:\/\/doi.org\/10.1016\/j.rpsm.2018.03.006","relation":{},"ISSN":["1888-9891"],"issn-type":[{"value":"1888-9891","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antipsic\u00f3ticos inyectables de liberaci\u00f3n prolongada para el tratamiento de la esquizofrenia en Espa\u00f1a","name":"articletitle","label":"Article Title"},{"value":"Revista de Psiquiatr\u00eda  y Salud Mental","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpsm.2018.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 SEP y SEPB. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}